Calvert et al., for instance, demonstrated via in silico and wet-bench investigations that non-mutated isocitrate dehydrogenase 1 (IDH1) is often overexpressed in primary GBM and that genetic and pharmacological inactivation leads to reduction of GBM tumor growth (153). The gene discussed is IDH1; the disease is neoplasm.